Latest Neuroendocrine tumor Stories
BOSTON, Jan. 20, 2011 /PRNewswire-USNewswire/ -- Through a grant provided by the Caring for Carcinoid Foundation (www.caringforcarcinoid.org), researchers at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center have discovered several key mutations in pancreatic neuroendocrine tumors.
John Hopkins University researchers said on Thursday that they have discovered the reason some people are able live for years with the same kind of rare pancreatic cancer that has inflicted people like Apple's CEO Steve Jobs.
NEW YORK, Dec. 2, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc.
COLUMBIA, Md., Nov. 2, 2010 /PRNewswire/ -- Celsion Corporation (Nasdaq: CLSN) today announced that the company has been awarded a $244,000 grant under the Qualifying Therapeutic Discovery Project (QTDP) program under The Patient Protection and Affordable Care Act of 2010 (PPACA).
The results of a large Phase-III clinical trial have shown that the drug everolimus delays tumor progression in patients with a hard-to-treat group of rare cancers that affect particular hormone-producing cells.
NEW YORK, Oct. 12 /PRNewswire/ -- The World NET Community announces the first Worldwide NET Cancer Awareness Day on November 10, 2010 to raise awareness about cancers called neuroendocrine tumors (NETs) and the need for timely detection and diagnosis.
EAST HANOVER, N.J., Sept.
Researchers uncover a mechanism that determines prostate cancer aggressiveness, providing new targets for diagnosis and treatment.
EAST HANOVER, N.J., July 1 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that results of a Phase III study show AfinitorÂ® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET).
EAST HANOVER, N.J., June 3 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that a Phase III study of AfinitorÂ® (everolimus) tablets plus best supportive care met its primary endpoint, showing the drug significantly extended progression-free survival, or time without tumor growth, in patients with advanced pancreatic neuroendocrine tumors (NET).